FIELD: medicine; pharmaceuticals.
SUBSTANCE: disclosed is a pharmaceutical composition comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, reducing the severity or symptomatic treatment of CFTR mediated diseases, such as cystic fibrosis, methods of production, methods of administration and kit thereof.
EFFECT: presented are pharmaceutical compositions for treating diseases mediated by a transmembrane regulator of cystic fibrosis CFTR.
43 cl, 7 tbl, 12 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING PHARMACEUTICAL COMPOSITIONS FOR TREATING CFTR MEDIATED DISEASES | 2014 |
|
RU2718044C2 |
| HIGH-PERFORMANCE TEST HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHOD | 2015 |
|
RU2691136C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES MEDIATED BY CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | 2015 |
|
RU2744460C2 |
| NEW TREATMENT | 2015 |
|
RU2688191C2 |
| SOLID FORMS OF (R)-1-(2,2-DIFLUOROBENZO[d][1,3]DIOXOL-5-YL)-N-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANE CARBOXAMIDE | 2011 |
|
RU2573830C2 |
| SOLID FORMS OF (R)-1-(2, 2-DIFLUOROBENZO[D][1, 3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL) CYCLOPROPANECARBOXAMIDE | 2011 |
|
RU2711481C2 |
| METHOD FOR OBTAINING MODULATORS OF CYSTIC FIBROUSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | 2010 |
|
RU2553989C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CYSTIC FIBRIOSIS | 2019 |
|
RU2822220C2 |
| PHARMACEUTICAL COMPOSITION AND ITS ADMINISTERING | 2013 |
|
RU2802442C2 |
| PHARMACEUTICAL COMPOSITION AND INTRODUCTION THEREOF | 2013 |
|
RU2692779C2 |
